Company Profile
Oxford Immunotec Ltd. is a UK-based manufacturer of immunodiagnostics, headquartered in Abingdon, Oxfordshire, United Kingdom. Founded in 2002, the company operates as a subsidiary of Revvity (NYSE: RVTY), serving diagnostic laboratories, hospitals, and public health institutions in over 50 countries. The North American headquarters is located in Marlborough, Massachusetts, USA.
Core Products & Technologies
Infectious Disease Diagnostics
• T-SPOT.TB: A cellular blood test detecting latent and active TB infection via patented T-cell measurement
• T-SPOT.CMV: An immune response assay for cytomegalovirus management in transplant patients
• C6 Lyme ELISA Test: A serological diagnostic for Lyme disease detection
T-Cell Measurement Technologies
• T-Cell Select™: A magnetic bead-based reagent kit for blood sample preparation
• T-Cell Xtend® Reagent: An antibody complex allowing blood samples to be processed up to 32 hours after venepuncture
Market Position & Certifications
Oxford Immunotec holds a specialized leadership position in the global immunodiagnostics market, competing with Qiagen and bioMerieux. Key strengths include:
• 20+ years of UK engineering heritage
• T-SPOT Technology: Patented T-cell measurement platform for immune-regulated conditions
• Regulatory compliance: CE marked, FDA approved, Health Canada licensed, NMPA registered (China)
• Global service network: Localized technical support across major markets
Corporate Timeline
2002 — Founded based on world-leading research at the University of Oxford
2004 — T-SPOT.TB receives CE mark approval in Europe
2005 — T-SPOT.TB licensed by Health Canada
2008 — T-SPOT.TB receives FDA pre-market approval in the United States
2013 — Listed on the Nasdaq stock exchange
2021 — Acquired by PerkinElmer for $591 million
2023 — Integrated into Revvity brand while retaining Oxford Immunotec product identities
Target Markets & Applications
• Tuberculosis Screening: T-SPOT.TB for latent and active TB detection in clinical and public health laboratories
• Transplant Monitoring: T-SPOT.CMV for CMV immune status assessment in solid organ and stem cell transplant recipients
• Infectious Disease Diagnostics: Lyme disease and other immune-regulated condition tests
Contact Information
Global Headquarters
Address: 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, United Kingdom
North American HQ: Marlborough, Massachusetts, USA
Parent Company
Revvity, Inc.
Address: 940 Winter Street, Waltham, Massachusetts 02451, USA
Stock: NYSE: RVTY
Website: revvity.com
Investor Relations: ir.revvity.com
